Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | CXCR2 | P25025 | 4/20 | 0.33 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.33 |
| ▸ | TTR | P02766 | 1/20 | 0.32 |
| ▸ | LIPE | Q05469 | 2/20 | 0.32 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | MGLL | Q99685 | 1/20 | 0.31 |
| ▸ | CCR6 | P51684 | 1/20 | 0.31 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17386366 | 0.91 | UCHL1 (0.36) | TDP1L3MBTL1CXCR2MAPK14LIPE | |
| SCHEMBL17429672 | 0.86 | UCHL1 (0.36) | TDP1L3MBTL1CXCR2TTRUCHL1 | |
| SCHEMBL17429652 | 0.85 | UCHL1 (0.33) | TDP1CXCR2MAPK14UCHL1ALDH1A1 | |
| SCHEMBL17386122 | 0.82 | UCHL1 (0.39) | TDP1L3MBTL1CXCR2TTRUCHL1 | |
| SCHEMBL23803972 | 0.79 | NLRP3 (0.40) | UCHL1MGLLMAPT | |
| SCHEMBL31092565 | 0.79 | MAPT (0.39) | TDP1L3MBTL1CXCR2TTRLIPE | |
| SCHEMBL17386167 | 0.78 | EGFR (0.43) | LIPEUCHL1ALDH1A1MAPT | |
| SCHEMBL26926518 | 0.77 | SMPD1 (0.47) | ALDH1A1MGLL | |
| SCHEMBL17385776 | 0.76 | UCHL1 (0.38) | CXCR2MAPK14UCHL1ALDH1A1CCR6 | |
| SCHEMBL5899519 | 0.74 | MAPT (0.50) | UCHL1ALDH1A1MGLLMAPTPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9643946-B2 | Tricyclic compound and use thereof | SK CHEMICALS CO., LTD. (KR) | 2017-05-09 | — | — | US | disclosed |
| US-20160009677-A1 | TRICYCLIC COMPOUND AND USE THEREOF | SK CHEMICALS CO., LTD. (KR) | 2016-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160009677-A1 | TRICYCLIC COMPOUND AND USE THEREOF | GPR65, GPR119, GPR35 | TDP1 4431/4885L3MBTL1 4322/4885CXCR2 461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.